Comparison · NCT03190694-sae
Dapagliflozin 10mg Tablet vs Placebo Matching Dapagliflozin Tablet: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dapagliflozin 10mg Tablet vs Placebo Matching Dapagliflozin Tablet: serious adverse events. Trial comparisons, record NCT03190694-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03190694-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0189 | 0.00334 | 0.0994 | wilson | |
| Risk in group 2 | 0.0192 | 0.0034 | 0.101 | wilson | |
| Risk difference, group 1 minus group 2 | -0.000363 | -0.0838 | 0.0817 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.981 | 0.063 | 15.3 | log | |
| Odds ratio, group 1 over group 2 | 0.981 | 0.0597 | 16.1 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Dapagliflozin 10mg Tablet than on Placebo Matching Dapagliflozin Tablet | 2,760 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dapagliflozin 10mg Tablet | 10 mg Green, plain, diamond shaped, film coated tablet (orally)~Dapagliflozin 10mg: Tablet | 1 | 53 | EG000 |
| Group 2 | Placebo Matching Dapagliflozin Tablet | Green, plain, diamond shaped, film coated tablet. Does not contain active ingredient~Dapagliflozin 10mg: Tablet | 1 | 52 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From the time of signing the informed consent and throughout the study, including the run-in and wash-out periods, until the follow-up visit 6 weeks after the last treatment period.
Source ClinicalTrials.gov
Trial
- Title
- Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria
- NCT number
- NCT03190694
- Phases
- PHASE2
- Conditions
- Chronic Kidney Diseases, Proteinuria
- Interventions
- Dapagliflozin 10mg
- Lead sponsor
- Hiddo Lambers Heerspink
- Results first posted
- 2024-06-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03190694?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03190694-sae